Robert Hillman is the founder of CeleCor Therapeutics. CeleCor Therapeutics has raised $47M in total funding. Latest round: Series A. Based in Del Mar, CA.
Robert S. Hillman is the Co-Founder, President, and CEO of CeleCor Therapeutics, which he co-founded in July 2017. He leads the company in developing novel anti-platelet agents for heart attack patients, including Disaggpro™ (zalunfiban) for STEMI patients. Hillman has guided CeleCor Therapeutics through a multinational Phase 3 registrational study for its investigational heart-attack drug.
Full founder directory · Investor directory · Company funding database · Fundraising library